Gainers
- NeuroMetrix NURO stock moved upwards by 29.0% to $3.65 during Friday's after-market session. This security traded at a volume of 455.8K shares come close, making up 519.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $26.0 million.
- Aptinyx APTX stock moved upwards by 12.55% to $0.39. The company's market cap stands at $26.4 million.
- Lipocine LPCN shares increased by 9.89% to $0.5. The market value of their outstanding shares is at $44.2 million.
- CNS Pharmaceuticals CNSP stock rose 8.97% to $0.21. The company's market cap stands at $8.4 million.
- Exicure XCUR stock increased by 8.23% to $1.84. The market value of their outstanding shares is at $9.1 million.
- Mainz Biomed MYNZ shares moved upwards by 7.83% to $7.02. The market value of their outstanding shares is at $101.6 million.
Losers
- Inventiva IVA shares fell 18.9% to $5.72 during Friday's after-market session. Inventiva's trading volume hit 355.8K shares by close, accounting for 4289.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $241.0 million.
- Kala Pharmaceuticals KALA stock fell 7.34% to $0.25. The market value of their outstanding shares is at $18.3 million.
- Acorda Therapeutics ACOR shares decreased by 5.41% to $0.35. The company's market cap stands at $8.5 million.
- Heron Therapeutics HRTX stock decreased by 5.26% to $3.97. The market value of their outstanding shares is at $471.4 million.
- Unity Biotechnology UBX stock decreased by 4.47% to $0.37. At the close, Unity Biotechnology's trading volume reached 51.1K shares. This is 1.3% of its average volume over the last 100 days. The company's market cap stands at $51.9 million.
- Baudax Bio BXRX shares fell 4.3% to $0.22. This security traded at a volume of 74.4K shares come close, making up 4.5% of its average volume over the last 100 days. The company's market cap stands at $1.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in